References
- Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment – Where do we stand? A state of the art review. Cancer Treat Rev 2014;40:523–32.
- Tan JZ, Schlicht SM, Powell GJ, Thomas D, Slavin JL, Smith PJ, et al. Multidisciplinary approach to diagnosis and management of osteosarcoma – a review of the St Vincent's Hospital experience. Int Semin Surg Oncol 2006;3:38–46.
- Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, et al. Metastatic osteosarcoma. Cancer 2006;106:403–12.
- Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 1994;12:2614–20.
- Berrak SG, Pearson M, Berberoğlu S, Ilhan IE, Jaffe N. High-dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity. Pediatr Blood Cancer 2005;44:215–9.
- He A, Qi W, Huang Y, Sun Y, Shen Z, Zhao H, et al. Comparison of pirarubicin-based versus gemcitabine- docetaxel chemotherapy for relapsed and refractory osteosarcoma: A single institution experience. Int J Clin Oncol 2013;18:498–505.
- Grignani G, Palmerini E, Dileo P, Asaftei SD, D’Ambrosio L, Pignochino Y, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian Sarcoma Group study. Ann Oncol 2012;23:508–16.
- Abdeen A, Chou AJ, Healey JH, Khanna C, Osborne TS, Hewitt SM, et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 2009;115:5243–50.
- Versleijen-Jonkers YM, Vlenterie M, van de Luijtgaarden AC, van der Graaf WT. Anti-angiogenic therapy, a new player in the field of sarcoma treatment. Crit Rev Oncol Hematol 2014;2:1–14.
- Tanaka T, Yui Y, Naka N, Wakamatsu T, Yoshioka K, Araki N, et al. Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy. Clin Exp Metastasis 2013;30:369–79.
- van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379: 1879–86.
- Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression – implications for drug resistance. Nat Rev Clin Oncol 2013;10:571–87.
- Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753–9.